Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2006

View Archived Issues

Roche and Amira sign research collaboration and licensing option agreements

Cellegesic to be reviewed by FDA Advisory Committee in April

Preclinical findings show Miraxion has neuroprotective effects in Parkinson's

Second phase I trial begins for third-generation taxane TPI-287

Series B financing to support pipeline development at Xytis

Hana demonstrates bioequivalence of Zensana ondansetron oral spray

TAP terminates sublicensing agreement with Santarus

IND submission for BEMA LA for moderate to severe pain

Enrollment open in phase IIb kidney transplant study of ISA-247

Phase I study for PV-903 for treatment of recurrent miscarriages

Ibuprofen may delay or prevent PD

MUC1 immunoassay may detect pancreatic cancer

Neurocrine updates FDA review of indiplon NDAs

Hemopure to be submitted for European approval in mid-2006

EntreMed completes Miikana acquisition

PR Pharmaceuticals and OSI collaborate on sustained-release Macugen

GlobeImmune closes Series B financing

European orphan drug designation for Amplimexon in ovarian cancer

MRE-0094 enters phase II for chronic neuropathic diabetic foot ulcers

Phase III program commences for Vanquix for acute, repetitive epileptic seizures

New analogue of celecoxib mimics antitumor activity in MM without COX-2 inhibition

Novel antiinfective agents disclosed in recent Johnson & Johnson patent

Vitragan MAA accepted for review

Recent patents report new therapeutic agents for diabetes and other endocrine-related disorders

Fast track designation for FavId in B-cell follicular NHL

LSN-2120310's activity against a wide range of menopausal symptoms

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...